

**REMARKS**

Each of claims 1-28 have been amended to primarily to remove all multiple dependencies, thereby reducing the total claim number, and to enhance the clarity of the claim language and remove internal duplications in some cases. There is support in the specification and original claims for these amendments, and new matter is added.

Figure 1 is amended to use the nucleotide position numbering system of SEQ ID NO:1, which corresponds to the numbering used throughout the specification and in certain claims. New Figure 1 does not introduce new matter

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue.

If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. § 1.136, and any additional fees required under 37 C.F.R. § 1.136 for any necessary extension of time, or any other fees required to complete the filing of this response, may be charged to Deposit Account No. 50-0911. Please credit any overpayment to deposit Account No. 50-0911.

Dated: September 19 2005

Respectfully submitted,

By 

Shmuel Livnat

Registration No.: 33,949

MCKENNA LONG & ALDRIDGE LLP

1900 K Street, N.W.

Washington, DC 20006

(202) 496-7500

Attorneys for Applicant